Welcome to our dedicated page for CONCENTRA GROUP HOLDINGS PAREN SEC filings (Ticker: CON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Concentra Group Holdings Parent, Inc. (NYSE: CON) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a U.S. public issuer in the healthcare and occupational health services sector. Concentra files current reports on Form 8-K to communicate material events, including quarterly financial results, dividend declarations, share repurchase authorizations, and governance changes such as director appointments and executive equity awards.
Recent Form 8-K filings describe the company’s financial results for quarters ended June 30 and September 30, 2025, with accompanying press releases and presentations furnished as exhibits. These materials outline revenue performance, income from operations, patient visit metrics, and the expansion of Concentra’s network of occupational health centers and onsite health clinics. Other 8-K filings detail cash dividend declarations and the authorization of a share repurchase program, providing insight into the company’s capital allocation decisions.
Additional filings report governance-related events. For example, Concentra has filed 8-Ks regarding the appointment of new members to its Board of Directors and the grant of restricted stock to named executive officers under its equity incentive plan. These disclosures help investors understand changes in the company’s leadership and executive compensation structure. The company has also filed 8-Ks related to preliminary operational metrics and presentations at investor conferences.
Through Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain key points from documents such as Form 8-K and related exhibits. Real-time updates from the EDGAR system help ensure that new filings for CON are reflected promptly, while AI-generated highlights can assist in identifying important information about financial performance, dividends, share repurchases, and governance matters without reading every line of each filing.
Concentra Group Holdings Parent, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders on April 30, 2026 at 11:00 a.m. CDT. Stockholders of record as of March 5, 2026, when 128,507,289 common shares were outstanding, may vote online.
Investors are asked to elect three Class II directors for three-year terms, approve on a non-binding basis the compensation of named executive officers, and ratify PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026. The Board recommends voting FOR all three proposals.
The proxy describes Concentra’s governance structure, including a majority-independent seven-member Board, an independent Lead Director, and four fully independent committees. It also details executive pay philosophy emphasizing performance-based bonuses and equity, 2025 restricted stock grants (e.g., 225,000 shares to CEO William Newton), stock ownership guidelines, clawback and anti-hedging policies, and cybersecurity oversight under a NIST-based framework.
Concentra Group Holdings Parent, Inc. reported strong growth for Q4 and full-year 2025 and declared a cash dividend. Fourth-quarter revenue rose to $539.1 million, up 15.9% from Q4 2024, with net income increasing 58.7% to $36.2 million. Adjusted EBITDA reached $95.3 million, up 22.9%, helped by higher patient volumes and revenue per visit.
For 2025, revenue grew 13.9% to $2.16 billion and Adjusted EBITDA rose 14.6% to $431.9 million, while net income was roughly flat at $172.8 million. The company generated $197.8 million of Free Cash Flow and ended the year with a 3.4x net leverage ratio.
The board declared a quarterly cash dividend of $0.0625 per share, payable in March 2026 to stockholders of record in mid-March. For 2026, Concentra guides to revenue of $2.25–$2.35 billion, Adjusted EBITDA of $450–$470 million, Free Cash Flow of $200–$225 million, capital expenditures of $70–$80 million, and a net leverage ratio at or below 3.0x.
T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting a significant ownership stake in Concentra Group Holdings Par common stock. As of 12/31/2025, it beneficially owned 16,843,425 shares, representing 13.1% of the class, with sole voting and dispositive power over essentially all of these shares.
The filing explains that T. Rowe Price acts as an investment adviser and that its clients, not the adviser, ultimately receive dividends and sale proceeds. The T. Rowe Price Mid-Cap Value Fund holds 7,546,942 shares, or 5.9% of the class. The stake is certified as held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Concentra Group Holdings Parent, Inc. furnished an 8-K to share a press release with preliminary, unaudited results for certain operating metrics for the fourth quarter and fiscal year ended December 31, 2025. The press release is included as Exhibit 99.1.
The company also furnished an investor presentation (Exhibit 99.2) and an investor book (Exhibit 99.3) published in connection with the same press release. These materials are furnished under Items 2.02 and 7.01 of the Exchange Act and are not deemed filed or incorporated by reference into other securities filings.
Concentra Group Holdings Parent, Inc. furnished an investor presentation containing preliminary, unaudited operational metrics for the quarter ended December 31, 2025. The presentation, filed as Exhibit 99.1, will be used at the J.P. Morgan Healthcare Conference at 9:00 A.M. PT on January 14 and a recording will later be posted on the company’s investor relations website. The information is being provided under Items 2.02 and 7.01 and is designated as furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other Securities Act or Exchange Act filings.
Concentra Group Holdings Parent, Inc. reported an insider transaction by its Chief Executive Officer and director involving a gift of common stock. On December 17, 2025, the reporting person made a gift of 89,081 shares of common stock to the Cynthia Lee Newton Beneficiary Trust, recorded at a price of $0 per share under transaction code G.
Following the transaction, the reporting person holds 393,750 shares of common stock directly. The Form 4 also shows 89,081 shares held indirectly through the Cynthia Lee Newton Beneficiary Trust. The filing explains that the reporting person is not a trustee of the trust, does not control its investments, and therefore has no reportable pecuniary interest in the shares held by the trust.
Concentra Group Holdings Parent, Inc. executive Timothy F. Ryan reported a routine share withholding related to equity compensation. On 11/26/2025, 5,903 shares of common stock were disposed of at $21.04 per share under transaction code “F,” indicating shares were withheld to cover tax obligations from the vesting of restricted stock. After this transaction, he beneficially owned 114,097 shares of common stock directly. Ryan serves as Executive Vice President & Chief Legal Counsel, and this filing reflects administrative management of taxes on equity awards rather than an open-market sale.
Concentra Group Holdings Parent, Inc. reported an insider share disposition by one of its executives. On 11/26/2025, an officer disposed of 3,935 shares of common stock at $21.04 per share, leaving 76,163 shares beneficially owned after the transaction. The filing classifies the transaction under code F, and the explanation states that the shares were withheld to satisfy tax obligations arising from the vesting of restricted stock. The reporting person serves as Executive Vice President and Chief Operating Officer, Onsite Health & Telemedicine, and the ownership is reported as held directly.